



DT20 Rec'd PCT/PTO 12 JUN 2003 PCT

Docket No. 2458-4042US5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): DENTON, et al.

Group Art Unit: TBA

Serial No.: 10/019,342

Examiner: TBA

Filed: December 21, 2001

For: METHODS FOR OBTAINING AND USING HAPLOTYPE DATA

INFORMATION DISCLOSURE STATEMENT

Mail Stop _____
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:

2. For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.
_____.
_____.
4. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or


- 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
 - 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
 - 37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5. No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
 - A check in the amount of \$180.00 is enclosed in payment of the fee.
 - Charge the fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
 - a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
 - b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.
8. This Information Disclosure Statement is being filed in compliance with:
 - a. 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
 - b. 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
 - c. The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11

below.

9. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. This document is accompanied by a Search Report Communication which was cited in a corresponding PCT or Foreign counterpart application
11. A check in the amount of \$ _____ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
- Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2458-4042US5. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

By:


Eugene Moroz
Registration No. 25,237

Dated: June 10, 2003

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

FORM PTO-1449 INFORMATION DISCLOSURE CITATION		Attorney Docket: 2458-4042US5	Serial No.: 10/019,342
		Applicant: DENTON, et al.	
		Filing Date: December 21, 2001	Group Art Unit: TBA

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Name	Class	Sub-Class	Filing Date
	5,966,711	10/12/1999	Adams			
	6,043,040	03/28/2000	Acton			
	6,030,778	02/29/2000	Acton et al.			
	6,223,128 B1	4/24/2001	Allex et al.			
	5,121,320	6/9/1992	Aoki et al.			
	6,222,559 B1	4/24/2001	Asano et al.			
	6,185,561 B1	2/6/2001	Balaban et al.			
	6,081,786	06/27/2000	Barry et al.			
	6,188,988	02/13/2001	Barry et al.			
	5,874,256	02/23/1999	Bertina et al.			
	5,866,404	2/2/1999	Bradshaw et al.			
	6,020,126	2/1/2000	Carlsson et al.			
	6,219,674	04/17/2001	Classen			
	5,773,220	06/30/2000	Dekosky et al.			
	5,811,239	09/22/1998	Frayne			
	5,912,120	06/15/1999	Goldstein et al.			
	5,891,633	04/06/1999	Gonzalez et al.			
	5,297,288	3/22/1994	Hemminger et al.			
	5,762,876	6/9/1998	Lincoln et al.			
	5,811,235	09/22/1998	Jeffreys			
	5,853,989	12/29/1998	Jeffreys et al.			
	6,094,626	7/25/2000	Kephart et al.			
	5,361,351	11/1/1994	Lenkov et al.			
	5,953,727	9/14/1999	Maslyn et al.			
	6,189,013 B1	2/13/2001	Maslyn et al.			
	6,175,830 B1	1/16/2001	Maynard			
	5,648,482	07/15/1997	Meyer			
	4,706,192	11/10/1987	Nasu et al.			
	6,214,556 B1	4/10/2001	Olek et al.			
	5,561,754	10/1/1996	Oliver et al.			
	5,559,944	9/24/1996	Ono			
	5,834,183	11/10/1998	Orr et al.			
	5,876,933	03/02/1999	Perlin			
	5,632,041	5/20/1997	Peterson et al.			
	6,022,683	02/08/2000	Poirer			
	5,862,304	1/19/1999	Ravdin et al.			
	6,178,382	01/23/2001	Roederer et al.			
	6,141,657	10/31/2000	Rothberg et al.			
	5,972,614	10/26/1999	Ruano et al.			
	5,970,500	10/19/1999	Sabatini et al.			
	5,966,712	10/12/1999	Sabatini et al.			

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	